AIM ImmunoTech Shares Are Trading Higher After the Company Announced the Print Publication of the Data Analysis From Its Early Access Program Studying Ampligen.
AIM ImmunoTech Shares Are Trading Higher After the Company Announced the Print Publication of the Data Analysis From Its Early Access Program Studying Ampligen.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.